Alexandra Gerlach, Associate Editor

Talquetamab and teclistamab showed significant promise in a phase 1b/2 dose escalation and expansion trial.

New executive orders and legislation aim to lower prescription drug costs and enhance access to pharmacist services for seniors across the US.

The investigational blood test achieved 99% sensitivity and specificity.

The data from the 5-year analysis of arm C validate and support the efficacy and safety of zanubrutinib for treatment-naive patients with CLL/SLL harboring del(17p).

Pembrolizumab gains FDA approval as a groundbreaking neoadjuvant treatment for resectable locally advanced head and neck squamous cell carcinoma, enhancing patient outcomes.

Mitomycin intravesical solution is the first FDA-approved treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer.

Significant challenges persist, particularly in low- and middle-income countries.

Meloxicam injection gains FDA approval for effective management of moderate-to-severe pain, offering a nonopioid alternative in pain control strategies.

Cilta-cel shows promise as a CAR T-cell therapy, offering long-term remission for patients with relapsed/refractory multiple myeloma without maintenance treatment.

The FDA has approved a groundbreaking single-pill combination therapy for hypertension, enhancing cardiovascular health with triple-agent efficacy.

Ibrutinib plus venetoclax shows promising long-term survival rates, including those who are considered high risk.

Experts share insights on patient discussions and adverse effect management strategies in HER2 breast cancer.

Explore the latest advancements in myelofibrosis treatment, focusing on JAK inhibitors and pegylated interferons for improved patient outcomes.

The 2025 ASCO Annual Meeting discusses the latest advancements in understanding and treating precursor diseases.

Explore the complexities of managing toxicities in breast cancer treatments, including endocrine therapies, antibody drug conjugates, and immune checkpoint inhibitors.

Experts discuss BiTE therapy in treating lung cancers, focusing on innovative agents like tarlatamab and amivantimab, and their toxicity management.

MRD testing transforms multiple myeloma treatment, guiding personalized strategies and improving patient outcomes through innovative testing methods.

Explore how the gut microbiome influences cancer therapy responses, resistance mechanisms, and the potential of microbiota-focused strategies for improved outcomes.

Groundbreaking oncology drugs transform treatment for glioblastoma, HR+ breast cancer, and small cell lung cancer.

Enhanced dermatologic management reduces skin rash and improves quality of life for patients with EGFR-mutant non-small cell lung cancer.

Zongertinib shows significant benefits in managing symptoms and improving quality of life for patients with HER2-mutated non-small cell lung cancer.

Elranatamab shows promising efficacy and manageable safety in transplant-ineligible newly diagnosed multiple myeloma patients, highlighting its potential as a treatment option.

Daratumumab combined with VRd significantly improved outcomes in transplant-ineligible/transplant deferred patients with newly diagnosed multiple myeloma.

Epcoritamab shows impressive long-term remission rates in relapsed large B-cell lymphoma, highlighting its potential as a key treatment option.

This segment takes a deeper dive into toxicity management—focusing not just on what to monitor, but how institutions are putting these protocols into action in real-world clinical settings.

The data from the phase 3 SEQUOIA study are to be presented at the 2025 ASCO Annual Meeting.

Imetelstat shows promise in treating myelofibrosis, enhancing survival, and modifying disease biology in patients resistant to JAK inhibitors.

Physical activity significantly enhanced quality of life and reduced fatigue and depression in patients with newly diagnosed multiple myeloma.